1. Ariza M. Unión neuromuscular y relajantes musculares. Universidad nacional de Colombia. 2003 [Documento en línea]. Disponible en: http://www.anestesianet.com/unal/rnm.htm. Fecha de recuperación: 24 de Julio de 2013.

2. De Boer HD, Van Egmond J, Driessen JJ, Booij LH. Update on the management of neuromuscular block: focus on sugammadex. Neuropsychiatr Dis Treat. 2007; 3 (5): 539 – 544.

3. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound Rocuronium-induced neuromuscular block. Anesth Analg. 2007; 104 (3): 555 – 562.

4. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the Postanesthesia Care Unit. Anesthesiology. 2008; 109 (3): 389 - 398.

5. López E, Saldaña E, Peña L, Mata M. Monitorización de la relajación muscular. En: Borja de la Quintana F (ED.) Monitorización en anestesia, cuidados críticos y medicina de urgencias. Editorial Elsevier: Barcelona, España. 2004. pp. 444 - 461.

6. Miller RD. Sugammadex: An Opportunity to change the practice of Anesthesiology? Anesth Analg. 2007; 104 (3): 477 - 478.

7. Cammu G, De Kam PJ, Demeyer I, Decoopman M, Peeters PA, Smeets JM, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth. 2008; 100 (3): 373 – 379

8. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth. 2006; 96 (1): 36 – 43.

9. Suy K, Morias K, Cammu G, Hans P, Van Duijnhoven WG, Heeringa M, et al. Effective reversal of moderate Rocuronium- or Vecuronium-induced neuromuscular block with Sugammadex, a selective relaxant binding agent. Anesthesiology. 2007; 106 (2): 283 – 288.

10. Ortiz J. Consideraciones sobre actitudes erróneas en el uso de bloqueantes neuromusculares. Rev Esp Anestesiol Reanim. 2002; 49 (2): 65-68

11. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008; 100 (5): 622 – 630.

12. De Boer HD, Van Egmond J, Van de Pol F, Bom A, Booij LH. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth. 2006; 96 (4): 473 – 479.

13. De Boer HD, Van Egmond J, Van de Pol F, Bom A, Booij LH. Reversal of profound Rocuronium neuromuscular blockade by Sugammadex in anesthetized Rhesus monkeys. Anesthesiology. 2006; 104 (4): 718 – 723.

14. De Boer HD, Van Egmond J, Van de Pol F, Bom A, Booij LH. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth. 2006; 96 (2): 201 – 206.

15. Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, et al. Reversal of Rocuronium-induced Neuromuscular Blockade with Sugammadex in Pediatric and Adult Surgical Patients. Anesthesiology. 2009; 110 (2): 284 – 294.

16. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Østergaard D, Prins ME, et al. Reversal of Rocuronium-induced Neuromuscular Block by the Selective Relaxant Binding Agent Sugammadex. A Dose-finding and Safety Study. Anesthesiology. 2006; 104 (4): 667– 674.

17. Della Rocca G, Pompei L. A novel approach to reversal of neuromuscular blockade. Minerva Anestesiol. 2009; 75 (5): 349 - 351.

18. Pühringer FK, Rex C, Sielenkämper Aw, Claudius C, Larsen PB, Prins ME, et al. Reversal of profound, high-dose Rocuronium–induced neuromuscular blockade by Sugammadex at two different time points. An international, multicenter, randomized, dose-finding, safety assessor–blinded, phase II trial. Anesthesiology. 2008; 109 (2): 188 – 197.

19. Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, et al. Early Reversal of Profound Rocuronium-induced Neuromuscular Blockade by Sugammadex in a Randomized Multicenter Study. Efficacy, Safety, and Pharmacokinetics. Anesthesiology. 2007; 106 (5): 935 – 943.

20. Jones RK, Caldwell JE, Brull SJ, Soto RD. Reversal of profound Rocuronium-induced blockade with Sugammadex. A randomized comparison with neostigmine. Anesthesiology. 2008; 109 (5): 816 – 824.

21. Gijsenbergh F, Ramael S, Houwing N, van Lersel T. First Human Exposure of Org 25969, a novel agent to reverse the action of Rocuronium Bromide. Anesthesiology. 2005; 103 (4): 695 – 703.

22. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Comparison with Neostigmine–Glycopyrrolate and Edrophonium–Atropine. Anesth Analg. 2007; 104 (3): 569 – 574.

23. Pimienta S. Efectividad de Sugammadex en la reversión del bloqueo neuromuscular en la población pediátrica. Tesis de Grado. Programa de Especialización en Anestesiología. Universidad del Zulia. 2011. [Tesis en línea]. Disponible en: http://tesis.luz.edu.ve/tde_busca/arquivo.php?codArquivo=3917. Fecha de recuperación: 21 de Julio de 2013.

24. Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by Sugammadex administered three minutes after Rocuronium. A comparison with spontaneous recovery from Succinylcholine. Anesthesiology. 2009; 110 (5): 1020 – 1025.

25. Ploeger BA, Smeets J, Strougo A, Drenth HJ, Ruigt G, Houwing N, et al. Pharmacokinetic–Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex. Anesthesiology. 2009; 110 (1): 95 – 105.

26. Lenz A, Hill G, White PF. Emergency use of Sugammadex after failure of standard reversal drugs. Anesth Analg. 2007; 104 (3): 585 – 586.

27. Naguib M. Sugammadex: Another Milestone in Clinical Neuromuscular Pharmacology. Anesth Analg. 2007; 104 (3): 575 – 81.

28. De Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of Rocuronium-induced (1.2 mg/kg) profound neuromuscular block by Sugammadex. A multicenter, dose-finding and safety study. Anesthesiology. 2007; 107 (2): 239–44

29. McDonnell NJ, Pavy TJ, Green LK, Platt PR. Sugammadex in the management of rocuronium-induced anaphylaxis. Br J Anaesth. 2011; 106 (2): 199 – 201.

30. Molina AL, de Boer HD, Klimek M, Heeringa M, Klein, J. Reversal of rocuronium-induced (1.2 mg kg-1) profound neuromuscular block by accidental high dose of sugammadex (40 mg kg-1). Br J Anaesth. 2007; 98 (5): 624 – 627.

31. Ortiz JR, Pérez J. Reversión del bloqueo neuromuscular residual por atracurio y vecuronio con dosis bajas de neostigmina. An Sist Sanit Navar. 2006; 29 (2): 189 - 198.

32. Vanacker BF, Vermeyen KM, Struys MM, Rietbergen H, Vandermeersch E, Saldien V, et al. Reversal of Rocuronium-induced neuromuscular block with the novel drug Sugammadex is equally effective under maintenance anesthesia with Propofol or Sevoflurane. Anesth Analg. 2007; 104 (3): 563 – 568